A systematic literature review of the economic impact of ankylosing spondylitis.

This article reviews the last decade studies on the economic impact of ankylosing spondylitis (AS). Interestingly, a common observation is that in AS indirect costs are higher than the use of direct healthcare resources. Country, age, gender, and severity of the diseases impact on per patient annual costs AS related. Different payment and reimbursement regimes may impact on the amount and distribution of indirect costs. The differences observed among countries on absolute and relative (compared with direct costs) amounts of indirect costs can be explained with the capability of a country of actually measure productivity losses and indirect costs. Low indirect costs without other indicators should not be considered as a sign of efficiency in AS care, but may be due to an underestimation of AS-related costs; as a consequence, indirect costs may be a net loss for patients that nobody can repay. A private insurance reimbursement regime has the highest capability of inducing players to define, select and actually identify indirect costs better than in different reimbursement regimes. Therefore indirect costs may become very high in case of private insurance regimes because of their more detailed identification.

[1]  Giuseppe Turchetti,et al.  Health Technology Assessment , 2010, IEEE Engineering in Medicine and Biology Magazine.

[2]  V. Lee,et al.  Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. , 2008, Rheumatology.

[3]  Jinoos Yazdany,et al.  Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. , 2012, Clinical and experimental rheumatology.

[4]  L. Quine,et al.  Living with Ankylosing Spondylitis , 2009, Journal of health psychology.

[5]  D. M. van der Heijde,et al.  Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost , 2010, Annals of the rheumatic diseases.

[6]  Giuseppe Turchetti,et al.  Systemic vasculitis: how little we know about their societal and economic burden. , 2012, Clinical and experimental rheumatology.

[7]  P. Andlin-Sobocki,et al.  Costs and quality of life of patients with ankylosing spondylitis in Canada. , 2006, The Journal of rheumatology.

[8]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: where are we today? , 2012, Clinical and experimental rheumatology.

[9]  G. Kobelt,et al.  The burden of ankylosing spondylitis in Spain. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  L. Tam,et al.  The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. , 2007, The Journal of rheumatology.

[11]  V. S. Gordeev,et al.  Role of contextual factors in health-related quality of life in ankylosing spondylitis , 2009, Annals of the rheumatic diseases.

[12]  S. van der Linden,et al.  Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[13]  M. Younes,et al.  Socioeconomic impact of ankylosing spondylitis in Tunisia. , 2010, Joint, bone, spine : revue du rhumatisme.

[14]  R. Ara,et al.  The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. , 2008, Rheumatology.

[15]  I. Olivieri,et al.  Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. , 2012, Clinical and experimental rheumatology.

[16]  D. Huscher,et al.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany , 2006, Annals of the rheumatic diseases.

[17]  S. van der Linden,et al.  Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[18]  A. Boonen,et al.  A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[19]  M. Dougados,et al.  Costs of ankylosing spondylitis in three European countries: the patient’s perspective , 2003, Annals of the rheumatic diseases.

[20]  A. Boonen,et al.  The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.

[21]  Giuseppe Turchetti,et al.  The rationale of pharmacoeconomic analysis in rheumatologic indications. , 2012, Clinical and experimental rheumatology.

[22]  Giuseppe Turchetti,et al.  Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. , 2012, Clinical and experimental rheumatology.

[23]  R. Rafia,et al.  Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. , 2012, Clinical and experimental rheumatology.

[24]  A. Boonen,et al.  Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.

[25]  L. Jacobsson,et al.  Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care , 2010, The Journal of Rheumatology.

[26]  M. Dougados,et al.  Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries , 2002, Annals of the rheumatic diseases.

[27]  Functional disability predicts total costs in patients with ankylosing spondylitis. , 2002 .

[28]  M. Ferraz,et al.  Resource utilisation and cost of ankylosing spondylitis in Brazil. , 2010, Clinical and experimental rheumatology.

[29]  M. Dougados,et al.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries , 2003, Annals of the rheumatic diseases.